Lilly Expects Mounjaro To Benefit From Novo Nordisk Cardiovascular Trial
An exec said results from the SELECT trial of Wegovy could benefit the GLP-1 agonist class, given that employers tend to opt into drug classes when covering obesity treatments.
An exec said results from the SELECT trial of Wegovy could benefit the GLP-1 agonist class, given that employers tend to opt into drug classes when covering obesity treatments.